β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction

For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (L...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of the American College of Cardiology Ročník 69; číslo 22; s. 2710
Hlavní autori:	Dondo, Tatendashe B, Hall, Marlous, West, Robert M, Jernberg, Tomas, Lindahl, Bertil, Bueno, Hector, Danchin, Nicolas, Deanfield, John E, Hemingway, Harry, Fox, Keith A A, Timmis, Adam D, Gale, Chris P
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 06.06.2017
Predmet:	Adrenergic beta-Antagonists - administration & dosage Aged Dose-Response Relationship, Drug Electrocardiography Female Follow-Up Studies Heart Failure - complications Heart Failure - drug therapy Hospital Mortality - trends Humans Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - mortality Propensity Score Prospective Studies Registries Survival Rate - trends United Kingdom - epidemiology Ventricular Dysfunction - complications Ventricular Dysfunction - drug therapy NSTEMI preserved left ventricular systolic function STEMI average treatment effect survival propensity score
ISSN:	1558-3597, 1558-3597
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality. Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819). Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).
AbstractList	For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality.BACKGROUNDFor acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality.The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD).OBJECTIVESThe goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD).This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality.METHODSThis cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality.Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819).RESULTSOf 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819).Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).CONCLUSIONSAmong survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654). For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality. Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819). Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).
Author	Hemingway, Harry West, Robert M Dondo, Tatendashe B Jernberg, Tomas Gale, Chris P Lindahl, Bertil Fox, Keith A A Hall, Marlous Bueno, Hector Danchin, Nicolas Deanfield, John E Timmis, Adam D
Author_xml	– sequence: 1 givenname: Tatendashe B surname: Dondo fullname: Dondo, Tatendashe B organization: Medical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom – sequence: 2 givenname: Marlous surname: Hall fullname: Hall, Marlous organization: Medical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom – sequence: 3 givenname: Robert M surname: West fullname: West, Robert M organization: Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom – sequence: 4 givenname: Tomas surname: Jernberg fullname: Jernberg, Tomas organization: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden – sequence: 5 givenname: Bertil surname: Lindahl fullname: Lindahl, Bertil organization: Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden – sequence: 6 givenname: Hector surname: Bueno fullname: Bueno, Hector organization: Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Instituto de Investigación i+12 and Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain – sequence: 7 givenname: Nicolas surname: Danchin fullname: Danchin, Nicolas organization: Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France; Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris-Descartes, Paris, France – sequence: 8 givenname: John E surname: Deanfield fullname: Deanfield, John E organization: National Institute for Cardiovascular Outcomes Research, University College London, London, United Kingdom – sequence: 9 givenname: Harry surname: Hemingway fullname: Hemingway, Harry organization: University College London, London, and Farr Institute of Health Informatics Research, London, United Kingdom – sequence: 10 givenname: Keith A A surname: Fox fullname: Fox, Keith A A organization: Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom – sequence: 11 givenname: Adam D surname: Timmis fullname: Timmis, Adam D organization: The National Institute for Health Biomedical Research Unit, Bart's Heart Centre, London, United Kingdom – sequence: 12 givenname: Chris P surname: Gale fullname: Gale, Chris P email: c.p.gale@leeds.ac.uk organization: Medical Research Council Bioinformatics Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom; Department of Cardiology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom. Electronic address: c.p.gale@leeds.ac.uk
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28571635$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtOwzAYhC1URFvgAiyQl2wSbCeOk2UpFJBAsOCxrP7af4RLahfbkei1OAhnouIhsZqR5ptZzJgMnHdIyBFnOWe8Ol3mS9A6F4yrnBW5VPUOGXEp66yQjRr880MyjnHJGKtq3uyRoail4lUhR-T98yM767x-xRApOENvfUjQ2bShkzZhoBPdJ6S3G68hGAsdvXYtBJ2sd9Q6eg_JokuRPtv04vtErxBCojOwXR-Q-kCftnGwuu8g0PNNbHv3XT4guy10EQ9_dZ88zi4eplfZzd3l9XRyk-mqKlNmtKzLclGIRYuCGdEoaYxmBdRcaaU1Q4MNr2QtoC1Z27QVcoaqgUVZCEAj9snJz-46-LceY5qvbNTYdeDQ93HOGybV9qOm2qLHv2i_WKGZr4NdQdjM_94SX99Pcho
CitedBy_id	crossref_primary_10_1016_j_amjcard_2023_04_042 crossref_primary_10_1097_MCA_0000000000001568 crossref_primary_10_1136_heartjnl_2020_316605 crossref_primary_10_3390_jcm13154416 crossref_primary_10_1016_j_repc_2018_10_005 crossref_primary_10_1016_j_ancard_2021_08_009 crossref_primary_10_1016_j_amjcard_2020_12_044 crossref_primary_10_1093_ehjcvp_pvab060 crossref_primary_10_1161_JAHA_124_034870 crossref_primary_10_1161_JAHA_117_007631 crossref_primary_10_1371_journal_pone_0255462 crossref_primary_10_1016_j_bioactmat_2021_07_011 crossref_primary_10_1109_ACCESS_2020_3014724 crossref_primary_10_3389_fphar_2022_1040710 crossref_primary_10_1016_j_jacc_2023_04_003 crossref_primary_10_1177_00033197241227025 crossref_primary_10_1093_eurheartj_ehaa436 crossref_primary_10_2147_CLEP_S274466 crossref_primary_10_1016_j_ahj_2018_10_005 crossref_primary_10_1016_j_jacc_2019_04_067 crossref_primary_10_1016_j_medcli_2019_11_008 crossref_primary_10_1161_CIRCOUTCOMES_123_010078 crossref_primary_10_1177_0267659119878396 crossref_primary_10_3389_fcvm_2022_779462 crossref_primary_10_1161_JAHA_124_037401 crossref_primary_10_1007_s40256_019_00338_4 crossref_primary_10_1016_j_phrs_2021_105614 crossref_primary_10_1093_eurheartj_ehaf170 crossref_primary_10_1016_j_hlc_2019_05_179 crossref_primary_10_1038_s41598_020_60528_y crossref_primary_10_1186_s12872_021_01850_9 crossref_primary_10_1016_j_jacc_2019_03_493 crossref_primary_10_1161_CIRCINTERVENTIONS_120_010159 crossref_primary_10_1161_JAHA_122_028976 crossref_primary_10_17816_medjrf677312 crossref_primary_10_1007_s00228_020_02886_0 crossref_primary_10_1097_JCMA_0000000000000621 crossref_primary_10_1016_j_medcle_2019_11_012 crossref_primary_10_1093_eurheartj_ehae302 crossref_primary_10_1093_eurheartj_ehy339 crossref_primary_10_1016_j_ejim_2021_08_003 crossref_primary_10_1016_j_jacc_2017_04_017 crossref_primary_10_1016_j_repc_2020_07_017 crossref_primary_10_1016_j_mayocp_2019_05_033 crossref_primary_10_1016_j_repc_2021_02_005 crossref_primary_10_3390_jpm10040288 crossref_primary_10_1161_JAHA_118_009111 crossref_primary_10_1056_NEJMc2103291 crossref_primary_10_1016_j_jacc_2017_06_072 crossref_primary_10_1161_CIRCINTERVENTIONS_121_010720 crossref_primary_10_1016_j_carrev_2020_03_033 crossref_primary_10_1016_j_jjcc_2022_07_003 crossref_primary_10_1016_j_ijcard_2019_01_049 crossref_primary_10_1016_j_repc_2017_11_016 crossref_primary_10_1161_CIRCOUTCOMES_117_004096 crossref_primary_10_1016_j_hlc_2021_06_522 crossref_primary_10_1056_NEJMclde2410735 crossref_primary_10_1093_eurjpc_zwae298 crossref_primary_10_1016_j_therap_2019_02_001 crossref_primary_10_7759_cureus_91371 crossref_primary_10_1093_ehjcvp_pvaa029 crossref_primary_10_1152_japplphysiol_00514_2019 crossref_primary_10_1111_imj_14750 crossref_primary_10_1155_2020_4351469 crossref_primary_10_1007_s10741_017_9660_1 crossref_primary_10_1038_s41598_020_79214_0 crossref_primary_10_1016_j_jacc_2019_03_531 crossref_primary_10_1161_JAHA_117_007567 crossref_primary_10_1136_heartjnl_2022_322115 crossref_primary_10_1056_NEJMoa2401479 crossref_primary_10_1371_journal_pone_0201311 crossref_primary_10_3390_jcm12062162 crossref_primary_10_1007_s00228_025_03919_2 crossref_primary_10_1007_s41999_023_00899_3 crossref_primary_10_1007_s11883_024_01203_9 crossref_primary_10_1186_s12872_022_02631_8 crossref_primary_10_36290_kar_2019_026 crossref_primary_10_1056_NEJMoa2504735 crossref_primary_10_1016_j_repce_2018_12_003 crossref_primary_10_1093_ehjcvp_pvy034 crossref_primary_10_1097_HJH_0000000000001940 crossref_primary_10_1161_JAHA_124_039059 crossref_primary_10_1016_j_repc_2019_01_004 crossref_primary_10_1136_bmjopen_2024_086971 crossref_primary_10_1016_j_acvd_2022_10_007 crossref_primary_10_1097_CRD_0000000000000197 crossref_primary_10_1186_s13063_020_4214_6 crossref_primary_10_1016_j_jacasi_2023_02_006 crossref_primary_10_1371_journal_pone_0199347 crossref_primary_10_1016_j_jacc_2017_07_760 crossref_primary_10_1007_s10742_024_00333_6 crossref_primary_10_1016_j_amjcard_2017_07_036 crossref_primary_10_1161_CIRCOUTCOMES_118_005103 crossref_primary_10_1016_j_ahj_2019_09_013 crossref_primary_10_3390_jcm14010150 crossref_primary_10_1016_j_athoracsur_2020_04_127 crossref_primary_10_1093_ehjcvp_pvaf062 crossref_primary_10_1093_ehjcvp_pvac070 crossref_primary_10_1177_10742484241264673 crossref_primary_10_1016_j_ijcard_2020_06_021 crossref_primary_10_1007_s10198_020_01158_z crossref_primary_10_1016_j_hlc_2020_03_013 crossref_primary_10_1007_s40256_019_00361_5 crossref_primary_10_1007_s40256_020_00427_9 crossref_primary_10_1136_emermed_2021_211723 crossref_primary_10_1016_j_ahj_2023_01_014 crossref_primary_10_1016_j_repce_2017_10_003 crossref_primary_10_1161_CIR_0000000000001168 crossref_primary_10_1097_MD_0000000000030846 crossref_primary_10_3389_fphys_2019_00350 crossref_primary_10_3390_ijms25137295 crossref_primary_10_1016_j_jacadv_2025_101814 crossref_primary_10_1016_j_acvd_2022_09_004 crossref_primary_10_1093_eurheartj_ehad191 crossref_primary_10_1016_j_cjca_2025_01_031 crossref_primary_10_1016_j_repce_2019_02_010 crossref_primary_10_1080_14796678_2025_2464449 crossref_primary_10_3390_jcm14113969 crossref_primary_10_1016_j_carrev_2019_01_033 crossref_primary_10_1016_j_phymed_2024_155728 crossref_primary_10_1038_s41569_021_00573_w crossref_primary_10_1097_MD_0000000000035187 crossref_primary_10_1038_s41598_020_72232_y crossref_primary_10_1016_j_clinthera_2025_06_007 crossref_primary_10_1097_CD9_0000000000000073 crossref_primary_10_1097_MCA_0000000000000610 crossref_primary_10_1007_s10557_018_6818_6 crossref_primary_10_1038_s41572_019_0090_3 crossref_primary_10_1155_2022_3505228 crossref_primary_10_1093_ehjci_jeaf015 crossref_primary_10_1093_eurheartj_ehy811 crossref_primary_10_1136_heartjnl_2017_312322 crossref_primary_10_1016_j_cpcardiol_2022_101215 crossref_primary_10_1016_j_jemermed_2018_06_018 crossref_primary_10_1016_j_repce_2020_07_013 crossref_primary_10_1097_FJC_0000000000001221 crossref_primary_10_1007_s00380_021_01876_1 crossref_primary_10_1177_0003319718815241 crossref_primary_10_1097_FJC_0000000000001627 crossref_primary_10_1016_j_cjca_2020_01_024 crossref_primary_10_1002_clc_23898 crossref_primary_10_1016_j_dsx_2021_06_013 crossref_primary_10_1007_s10557_018_6829_3 crossref_primary_10_1016_j_repce_2017_11_022 crossref_primary_10_1002_clc_23807 crossref_primary_10_3390_cancers14040867 crossref_primary_10_1007_s00380_019_01387_0 crossref_primary_10_1016_j_jacadv_2024_101582 crossref_primary_10_1016_j_amjcard_2021_10_049 crossref_primary_10_1093_eurheartj_ehaa376 crossref_primary_10_1016_j_ijcard_2020_07_001 crossref_primary_10_1093_eurheartj_ehae177 crossref_primary_10_1093_ehjcvp_pvy005 crossref_primary_10_1002_phar_2110 crossref_primary_10_1016_j_amjms_2025_01_009 crossref_primary_10_1016_j_repc_2017_08_001 crossref_primary_10_1016_j_amjmed_2019_01_039 crossref_primary_10_1016_j_ahj_2018_12_015 crossref_primary_10_1080_17476348_2018_1419869 crossref_primary_10_1080_07853890_2020_1740938 crossref_primary_10_1097_MD_0000000000023987 crossref_primary_10_1016_j_repce_2021_04_004 crossref_primary_10_1177_2047487318784671 crossref_primary_10_1016_j_tcm_2017_12_014 crossref_primary_10_1124_pharmrev_124_001297
ContentType	Journal Article
Copyright	Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jacc.2017.03.578
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1558-3597
ExternalDocumentID	28571635
Genre	Multicenter Study Journal Article
GrantInformation_xml	– fundername: Medical Research Council grantid: MR/K006584/1 – fundername: Wellcome Trust grantid: 206470/Z/17/Z – fundername: Medical Research Council grantid: MC_PC_13041
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AAEDT AAEDW AAIKJ AAKUH AALRI AAOAW AAQFI AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ACGFO ACGFS ACIUM ACJTP ACPRK ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFCTW AFETI AFPUW AFRAH AFRHN AFTJW AGCQF AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 H13 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A NPM O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 RIG ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R 7X8 EFLBG ~HD
ID	FETCH-LOGICAL-c664t-dc5844b32bfe20d2975ddc03a817c7cc0ede916582af40f9f6e10e79ab432aed2
IEDL.DBID	7X8
ISICitedReferencesCount	196
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402134700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1558-3597
IngestDate	Thu Sep 25 08:44:47 EDT 2025 Mon Jul 21 05:50:30 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	22
Keywords	NSTEMI preserved left ventricular systolic function STEMI average treatment effect survival propensity score
Language	English
License	Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c664t-dc5844b32bfe20d2975ddc03a817c7cc0ede916582af40f9f6e10e79ab432aed2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.clinicalkey.es/playcontent/1-s2.0-S0735109717369103
PMID	28571635
PQID	1905735996
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1905735996 pubmed_primary_28571635
PublicationCentury	2000
PublicationDate	2017-06-06
PublicationDateYYYYMMDD	2017-06-06
PublicationDate_xml	– month: 06 year: 2017 text: 2017-06-06 day: 06
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of the American College of Cardiology
PublicationTitleAlternate	J Am Coll Cardiol
PublicationYear	2017
References	28935047 - J Am Coll Cardiol. 2017 Sep 26;70(13):1685-1686. doi: 10.1016/j.jacc.2017.07.760. 29268356 - J Thorac Dis. 2017 Oct;9(10):3616-3619. doi: 10.21037/jtd.2017.09.93. 28571636 - J Am Coll Cardiol. 2017 Jun 6;69(22):2721-2724. doi: 10.1016/j.jacc.2017.04.017. 28935048 - J Am Coll Cardiol. 2017 Sep 26;70(13):1685. doi: 10.1016/j.jacc.2017.06.072. 29268468 - J Thorac Dis. 2017 Nov;9(11):4191-4194. doi: 10.21037/jtd.2017.10.25.
References_xml	– reference: 28571636 - J Am Coll Cardiol. 2017 Jun 6;69(22):2721-2724. doi: 10.1016/j.jacc.2017.04.017. – reference: 29268468 - J Thorac Dis. 2017 Nov;9(11):4191-4194. doi: 10.21037/jtd.2017.10.25. – reference: 29268356 - J Thorac Dis. 2017 Oct;9(10):3616-3619. doi: 10.21037/jtd.2017.09.93. – reference: 28935048 - J Am Coll Cardiol. 2017 Sep 26;70(13):1685. doi: 10.1016/j.jacc.2017.06.072. – reference: 28935047 - J Am Coll Cardiol. 2017 Sep 26;70(13):1685-1686. doi: 10.1016/j.jacc.2017.07.760.
SSID	ssj0006819
Score	2.6155703
Snippet	For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. The goal of this study was... For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality.BACKGROUNDFor acute...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2710
SubjectTerms	Adrenergic beta-Antagonists - administration & dosage Aged Dose-Response Relationship, Drug Electrocardiography Female Follow-Up Studies Heart Failure - complications Heart Failure - drug therapy Hospital Mortality - trends Humans Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - mortality Propensity Score Prospective Studies Registries Survival Rate - trends United Kingdom - epidemiology Ventricular Dysfunction - complications Ventricular Dysfunction - drug therapy
Title	β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction
URI	https://www.ncbi.nlm.nih.gov/pubmed/28571635 https://www.proquest.com/docview/1905735996
Volume	69
WOSCitedRecordID	wos000402134700005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7cEC_uS90YwWswzTIzOUldSgVbenDprUxmwagktUnF_i1_iL_J95IUT4LgZW4PhnnbN28l5NQP4wiHpjjWMBc-KDHonDIWZJlLpZosFrJsFL7lvZ4YDKJ-HXDL67LKmU0sDbXOFMbIz8BxhdzHYSLnozcHt0ZhdrVeoTFPFn2AMqiYfPAzLZyJcrEHuEzhACmvm2aq-q5nuAuWdnEcchpy8TvELF1Ne-2_l1wnqzXIpK1KKjbInEk3yXK3TqNvkY-vT-cCvNgLYD8qU027JQgHQE5buDOcttSkMLQ7BUeHAvRKb1ILGoFMpElK-9Uw1pw-JsVTNiloB_SloG2ZYJE7zcb0AYPGSVnjSq-mOXpPJN4m9-3ru8uOU69gcBRjQeFoBQAliH0vtsZzNbbhaq1cX4omV1wp12gDADMUnrSBayPLTNM1PJJx4HvSaG-HLKRZavYI9RSgA4RXTJog1kI0LdgTEAUAOTZiokFOZm86BBHHvIVMTTbJhz-v2iC7FWOGo2oWx9ATIfz4_HD_D9QHZAX5XRZ6sUOyaEHBzRFZUu9Fko-PS9mBs9fvfgNF1dDz
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2-Blockers+and+Mortality+After+Acute+Myocardial+Infarction+in+Patients+Without+Heart+Failure+or+Ventricular+Dysfunction&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Dondo%2C+Tatendashe+B&rft.au=Hall%2C+Marlous&rft.au=West%2C+Robert+M&rft.au=Jernberg%2C+Tomas&rft.date=2017-06-06&rft.issn=1558-3597&rft.eissn=1558-3597&rft.volume=69&rft.issue=22&rft.spage=2710&rft_id=info:doi/10.1016%2Fj.jacc.2017.03.578&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon